0001104659-19-041021.txt : 20190718
0001104659-19-041021.hdr.sgml : 20190718
20190718190422
ACCESSION NUMBER: 0001104659-19-041021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190717
FILED AS OF DATE: 20190718
DATE AS OF CHANGE: 20190718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Read Simon
CENTRAL INDEX KEY: 0001688199
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37926
FILM NUMBER: 19962153
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
STREET 2: C/O RA PHARMACEUTICALS, INC.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001481512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262908274
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 401-4060
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
a4.xml
4
X0306
4
2019-07-17
0
0001481512
Ra Pharmaceuticals, Inc.
RARX
0001688199
Read Simon
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
Chief Scientific Officer
COMMON STOCK
2019-07-17
4
M
0
10000
2.87
A
16234
D
COMMON STOCK
2019-07-17
4
S
0
10000
32.9479
D
6234
D
Stock Options (Right to buy)
2.87
2019-07-17
4
M
0
10000
0
D
2026-06-16
Common Stock
10000
96142
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.57 to $33.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter.
/s/ David Lubner, Attorney-in-Fact for Simon Read
2019-07-18